Nerve-stimulation device enters human trials for cancer-related cachexia
The Terasaki Institute for Biomedical Innovation announced today that OnVagus, a medical device company incubating at the Institute, has received institutional and regulatory approval to begin the first human trial of its noninvasive nerve-stimulation device for patients experiencing cancer-related wasting.
Read original article on The Medical News →Related news
-
Single tRNA controls prostate cancer identity and treatment resistance
United Kingdom
-
Parasitic worms could hold the key to treating immune system diseases
United Kingdom
-
Why Trump just loosened the rules on 'dyed diesel' — normally a farm fuel
United States
-
Study may explain why IBD patients react to foods they once tolerated
United Kingdom
-
Canada recruits internationally educated health professionals. Credential recognition is only part of the challenge
United Kingdom
-
Brain immune cells protect neurons in Parkinson's disease by 'nibbling' harmful material
United Kingdom
-
Dementia status influences end-of-life care decisions despite advance directives
United Kingdom
-
Major global alliance invests billions to build predictive AI models of biology
United Kingdom